Comparative Pharmacology
Head-to-head clinical analysis: COPEGUS versus GANCICLOVIR SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COPEGUS versus GANCICLOVIR SODIUM.
COPEGUS vs GANCICLOVIR SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ribavirin is a nucleoside analogue that inhibits viral RNA synthesis by interfering with RNA capping and polymerase activity, and may also modulate immune responses.
Ganciclovir is a synthetic guanine derivative that inhibits viral DNA synthesis. It is phosphorylated to ganciclovir triphosphate by viral thymidine kinase (CMV UL97 gene product) and cellular kinases. Ganciclovir triphosphate competitively inhibits viral DNA polymerase (CMV UL54 gene product) and incorporates into viral DNA, causing chain termination.
800 mg orally twice daily to 1200 mg orally twice daily based on body weight (≤75 kg: 800 mg; >75 kg: 1200 mg), in combination with ribavirin, for 24 to 48 weeks depending on genotype.
5 mg/kg IV every 12 hours for 14-21 days for induction; 5 mg/kg IV once daily or 6 mg/kg IV once daily 5 days per week for maintenance. Oral ganciclovir not available as sodium salt.
None Documented
None Documented
Terminal elimination half-life is approximately 120-170 hours following multiple doses, supporting once-daily dosing with prolonged viral suppression.
Terminal half-life: 2.5-3.6 hours in normal renal function; prolonged in renal impairment (up to 30 hours in severe cases). Dosage adjustment required for CrCl <80 mL/min.
Ribavirin is primarily eliminated renally as unchanged drug (61%) and metabolites (30%); biliary/fecal excretion accounts for ~9%.
Renal: >90% unchanged drug via glomerular filtration and tubular secretion. Biliary/fecal: <1%.
Category C
Category D/X
Antiviral
Antiviral